Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02211222
Expanded Access Status : Approved for marketing
First Posted : August 7, 2014
Last Update Posted : March 16, 2016
Sponsor:
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
This Expanded Access Program (EAP) consists of a Prerandomization Phase and a Randomization Phase. Only subjects with radioiodine-refractory DTC who fulfill the eligibility criteria will be treated. These subjects will be treated until progression of disease or unacceptable toxicity.

Condition or disease Intervention/treatment
Differentiated Thyroid Cancer Drug: Lenvatinib

Layout table for study information
Study Type : Expanded Access
Official Title: An Open-Label, Randomized, Multicenter, Expanded Access Program With Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
Estimated Primary Completion Date : August 2015
Estimated Study Completion Date : June 2015

Resource links provided by the National Library of Medicine



Intervention Details:
  • Drug: Lenvatinib
    Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
    Other Name: E7080

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria

  1. Subjects must have histologically or cytologically confirmed diagnoses of one of the following DTC subtypes: a. Papillary thyroid cancer (PTC) i. Follicular variant ii. Variants (including but not limited to: tall cell, columnar cell, cribriform-morular, solid, oxyphil, Warthin's-like, trabecular, tumor with nodular fasciitis-like stroma, Hurthle cell variant of papillary carcinoma, poorly differentiated); b.Follicular thyroid cancer (FTC) i. Hurthle cell ii. Clear cell iii.Insular
  2. Subjects must be radioiodine-refractory or resistant within 12 months of radioiodine therapy and have one of the following:

    1. One or more lesions that do not demonstrate iodine uptake on any radioiodine scan
    2. One or more lesions that have substantially increased in size within 12 months of radioiodine therapy, despite demonstration of radioiodine activity at the time of that treatment by pre- or posttreatment scanning
    3. Cumulative activity of radioiodine of greater than 600 mCi or 22 gigabecquerels (GBq), with the last dose administered at least 6 months prior to study entry
  3. Subjects must have received and failed treatment with sorafenib for RR-DTC. This criterion will not apply outside the United States if sorafenib is not commercially available in the country where the subject resides.
  4. ECOG performance status of 0 to 2
  5. Blood pressure (BP) less than or equal to 150/90 mmHg at screening with or without antihypertensive medications and no change in antihypertensive medications within 1 week prior to Cycle 1 Day 1
  6. Creatinine clearance greater than or equal to 30 mL/min according to the Cockcroft and Gault formula
  7. Adequate bone marrow function

    • Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L
    • Hemoglobin greater than or equal to 9.0 g/dL (can be corrected by growth factor or transfusion)
    • Platelet count greater than or equal to 100 x 10^9/L
  8. Adequate liver function

    • Bilirubin less than or equal to 1.5 x upper limit of normal (ULN) except for unconjugated hyperbilirubinemia or Gilbert's syndrome
    • Alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 x ULN (less than or equal to 5 x ULN if subject has liver metastases). If ALP is greater than 3 x ULN (in the absence of liver metastases) or greater than 5 x ULN (in the presence of liver metastases) AND subjects are also known to have bone metastases, the liver-specific ALP must be separated from the total and used to assess the liver function instead of the total ALP
  9. Provide written informed consent
  10. Males and females age greater than or equal to 18 years at the time of informed consent
  11. All females must have a negative serum or urine pregnancy test. Females of childbearing potential and male subjects who are partners of women of childbearing potential must use or their partners must use a highly effective method of contraception

Exclusion Criteria

  1. Subjects having greater than 1+ proteinuria on urine dipstick at screening testing will undergo 24 h urine collection for quantitative assessment of proteinuria. Subjects with urine protein greater than or equal to 1 g/24 h will be ineligible.
  2. History of congestive heart failure with New York Heart Association (NYHA) Classification greater than II, unstable angina, myocardial infarction, serious cardiac arrhythmia, or stroke within the past 6 months
  3. Electrocardiogram (ECG) with QT interval (QTc) interval greater than or equal to 480 msec
  4. Existing anti-cancer therapy-related toxicities of grade greater than or equal to 2, except alopecia and infertility
  5. History of intolerance to or progression on prior treatment with lenvatinib that led to the discontinuation of lenvatinib
  6. Any history of or concomitant medical condition that, in the opinion of the investigator, would compromise subject's ability to safely complete the protocol
  7. Females who are pregnant (positive B-hCG test) or breastfeeding
  8. Eligible for any other lenvatinib study that is open for recruitment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02211222


Locations
Layout table for location information
United States, California
La Jolla, California, United States
Stanford, California, United States
Torrance, California, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Illinois
Chicago, Illinois, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, Michigan
Lansing, Michigan, United States
United States, New Hampshire
Lebanon, New Hampshire, United States
United States, New Jersey
Neptune, New Jersey, United States
United States, Ohio
Cleveland, Ohio, United States
United States, Oregon
Portland, Oregon, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
United States, Texas
Houston, Texas, United States
Sponsors and Collaborators
Eisai Inc.
Layout table for additonal information
Responsible Party: Eisai Inc.
ClinicalTrials.gov Identifier: NCT02211222    
Other Study ID Numbers: E7080-G000-398
First Posted: August 7, 2014    Key Record Dates
Last Update Posted: March 16, 2016
Last Verified: March 2016
Keywords provided by Eisai Inc.:
Thyroid Cancer
Radioiodine-Refractory
Differentiated
Additional relevant MeSH terms:
Layout table for MeSH terms
Thyroid Neoplasms
Thyroid Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Head and Neck Neoplasms
Lenvatinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action